D-Gam Human Anti-D Immunoglobulin Malta - English - Medicines Authority

d-gam human anti-d immunoglobulin

bio products laboratory limited - anti, d immunoglobulin, human - solution for injection - anti-d immunoglobulin, human 250 international unit(s)/millilitre - immune sera and immunoglobulins

RHOPHYLAC 1500IU human anti-D immunoglobulin solution for injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

rhophylac 1500iu human anti-d immunoglobulin solution for injection syringe

csl behring australia pty ltd - anti-d rho immunoglobulin, quantity: 1500 iu - injection, solution - excipient ingredients: chloride; glycine; sodium; albumin - prevention of rh sensitisation in rh(d)-negative females at or below child-bearing age and treatment of rh(d)-negative persons after incompatible transfusions of rh(d)-positive blood or other products containing red blood cells.

CSL HEPATITIS B IMMUNOGLOBULIN VF (human) 100IU injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

csl hepatitis b immunoglobulin vf (human) 100iu injection vial

csl behring australia pty ltd - human immunoglobulin g, quantity: 160 mg/ml; hepatitis b immunoglobulin, quantity: 100 iu - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - indications as at 8 august 2002 : hepatitis b immunoglobulin is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (<10iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive material or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin is also indicated for prophylaxis in infants born to hbsag-positive mothers. hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (<10iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

CSL Rh(D) IMMUNOGLOBULIN VF (human) 250 IU injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

csl rh(d) immunoglobulin vf (human) 250 iu injection vial

csl behring australia pty ltd - anti-d rho immunoglobulin, quantity: 250 iu; anti-d rho immunoglobulin, quantity: 10 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - rh(d) immunoglobulin is indicated for the prevention of rh sensitisation in rh(d)negative females at or below child bearing age.

CSL Rh(D) IMMUNOGLOBULIN VF (human) 625IU injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

csl rh(d) immunoglobulin vf (human) 625iu injection vial

csl behring australia pty ltd - anti-d rho immunoglobulin, quantity: 625 iu; anti-d rho immunoglobulin, quantity: 30 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - indications as at 6 august 2002 : rh(d) immunoglobulin is indicated for the prevention of rh sensitisation in rh(d) negative females at or below child bearing age.

Rhesonativ 625 IU/ml, solution for injection Malta - English - Medicines Authority

rhesonativ 625 iu/ml, solution for injection

octapharma (ip) limited - anti-d immunoglobulin, human - solution for injection - anti-d immunoglobulin, human 625 iu/ml - immune sera and immunoglobulins

Rhesonativ Solution for Injection 625IU/ml (1ml amp) Malta - English - Medicines Authority

rhesonativ solution for injection 625iu/ml (1ml amp)

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - anti, d immunoglobulin, human - solution for injection - anti-d immunoglobulin, human 625 iu/ml - immune sera and immunoglobulins

Rhesonativ Solution for Injection 625IU/ml (2ml amp) Malta - English - Medicines Authority

rhesonativ solution for injection 625iu/ml (2ml amp)

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - anti, d immunoglobulin, human - solution for injection - anti-d immunoglobulin, human 625 iu/ml - immune sera and immunoglobulins

D-Gam 50 micrograms/ml solution for injection Malta - English - Medicines Authority

d-gam 50 micrograms/ml solution for injection

bpl bioproducts laboratory gmbh dornhofstraße 34, 63263 neu-isenburg,, germany - anti, d immunoglobulin, human - solution for injection - anti-d immunoglobulin, human 250 iu/ml - immune sera and immunoglobulins

CSL HEPATITIS B IMMUNOGLOBULIN VF (human) 400IU injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

csl hepatitis b immunoglobulin vf (human) 400iu injection vial

csl behring australia pty ltd - hepatitis b immunoglobulin, quantity: 400 iu; human immunoglobulin g, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (<10iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.